98%
921
2 minutes
20
Purpose: Dexamethasone has shown promising efficacy in alleviating pain and enhancing outcomes undergoing TKA. However, an optimal route of administration, dosage, and treatment duration have not yet been established. This study is to assess the effects of intravenous dexamethasone administration on postoperative pain management and prognosis in patients undergoing TKA.
Methods: Data were retrieved from PubMed, Embase, the Cochrane Library, and Web of Science to compare the effects of intravenous dexamethasone administration versus non-administration on outcomes following TKA. Primary endpoints included pain scores and morphine consumption. Secondary endpoints comprised walking distance, ROM, patients requiring rescue analgesics and antiemetics, LOS, levels of CRP and IL-6, QoR, and the incidence of adverse events.
Results: This meta-analysis included 15 RCTs involving 2,584 patients. The study indicated that intravenous dexamethasone can decrease VAS scores at rest (24 h, 95% CI: -0.71 [-0.86, -0.55], I²=66%, P < 0.00001; 48 h, 95% CI: -0.30 [-0.43, -0.18], I²=46%, P < 0.00001) and movement (24 h, 95% CI: -0.89 [-1.23, -0.55], I²=91%,P < 0.00001; 48 h, 95% CI: -0.42 [-0.62, -0.23], I²=84%, P < 0.0001). Moreover, it can reduce morphine consumption (24 h, 95% CI: -3.06 [-4.82, -1.30], I²=46%, P = 0.0006; 48 h, 95% CI: -5.23 [-8.28, -2.18], I²=76%, P = 0.0008) and increase walking distances on postoperative days 1 to 3, and improve the ROM on postoperative day 1 to 2. Furthermore, intravenous dexamethasone reduced the need for requiring rescue analgesics and antiemetics, shortened LOS, lowered CRP and IL-6 levels, and improved the quality of life after TKA. The incidence of infection, gastrointestinal hemorrhage, wound healing, or deep vein thrombosis/pulmonary embolism did not differ significantly. Subgroup analyses revealed no significant differences between single-administration and repeat-administration groups, except in the context of rescue antiemetic requirements.
Conclusion: Our study revealed that a single intravenous dose of dexamethasone, ranging from 8 to 16 mg administered before or after the induction of anesthesia or one hour prior to surgery, is efficacious in diminishing postoperative pain and cumulative morphine consumption, reducing the necessity for rescue analgesics and antiemetics, and shorten LOS for TKA. Additionally, it contributed to an increase in postoperative walking distance, ROM, and overall quality of postoperative recovery.
Trial Registration: We conducted literature selection, eligibility criteria evaluation, data extraction and analysis on the research program registered in Prospero (CRD42024521224) in January 2025.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11761980 | PMC |
http://dx.doi.org/10.1007/s00423-025-03618-7 | DOI Listing |
Paediatr Anaesth
September 2025
Department of Otorhinolaryngology, Section of Pediatric Otorhinolaryngology, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
Introduction: Tonsillectomy is associated with a high rate of postoperative nausea and vomiting (PONV), ranging between 40% and 73%, and dexamethasone has been found to have a prophylactic effect on PONV in children undergoing tonsillectomy. In 2020, there was a sudden, severe shortage of intravenous dexamethasone given its role in treating patients with COVID-19. The primary aim of this study was to investigate the viability of an alternative: non-inferiority of oral versus intravenous dexamethasone for preventing PONV.
View Article and Find Full Text PDFJ Gen Fam Med
September 2025
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital Mahidol University Samut Prakan Thailand.
(GBS) is a rare cause of meningitis in healthy adults. We report the case of a healthy 33-year-old man with acute GBS meningitis who experienced relapsed high-grade fever and increased intracranial pressure following completing intravenous antibiotics. A short course of corticosteroids, along with additional antibiotics, improved the cerebrospinal fluid (CSF) profile, and no further complications occurred after the recurrent episodes.
View Article and Find Full Text PDFCase Rep Med
August 2025
Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
A 65-year-old woman presented with pneumococcal sepsis and meningitis. Despite appropriate antimicrobial therapy and intravenous (IV) dexamethasone, her mental status did not improve. Findings of brain imaging were suggestive of cerebral vasculitis.
View Article and Find Full Text PDFBMC Med
August 2025
Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Background: This phase I trial aimed to assess the pharmacokinetics (PK), safety, and preliminary efficacy of a single dose of HR20013 (mixed formulation of fosrolapitant and palonosetron) plus dexamethasone in patients with malignant solid tumors.
Methods: Solid tumor patients who were naive to cisplatin-based chemotherapy and scheduled to receive the single-day cisplatin-based chemotherapy were enrolled. Patients would receive a single intravenous infusion of HR20013 (Day 1) before cisplatin-based chemotherapy, alongside oral dexamethasone (Day 1, 12 mg, once a day; Day 2-4, 3.
Cureus
July 2025
Internal Medicine, AdventHealth Orlando, Orlando, USA.
Evans syndrome is a rare condition that can be seen among patients with pre-existing rheumatological disorders such as lupus, rheumatoid arthritis, or adult-onset Still's disease. There is an association between positive anti-phospholipid antibodies and the development of Evans syndrome, but the underlying pathophysiology remains unknown. To our knowledge, this is one of the few case reports to date that describes the development of Evans syndrome triggered by parvovirus B19 in patients with pre-existing positive antiphospholipid antibodies.
View Article and Find Full Text PDF